Teresa Maria Assunta Fasciana
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Teresa Maria Assunta Fasciana has a total of 260 co-authors. Here are the top co-authors by number of shared publications:
- Anna Giammanco
Legionella Reference Laboratory, University of Palermo, 90127 Palermo, Italy
14 shared publications - Antonio Cascio
University of Palermo
11 shared publications - Paola Di Carlo
Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo, 90127 Palermo, Italy
11 shared publications - Nicola Serra
Audiology Section, Department of Neuroscience and Reproductive Sciences and Dentistry, University of Naples Federico II, 80131 Naples, Italy
10 shared publications - Consolato Sergi
Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB T6G 2R3, Canada
7 shared publications - Giuseppina Capra
Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE) “G. D’Alessandro”, University of Palermo, Palermo, Italy
6 shared publications
Latest Publications
- Open Access
- 25 August 2026
- Published by MDPI AG in Microorganisms
- Vol. 14 (9) , 1886
Legionella pneumophila: A Microorganism with a Thousand Faces—From Environmental Complexity to Clinical and Technological Challenges
Legionella pneumophila epitomizes the concept of a microorganism with “a thousand faces”, reflecting its extraordinary ecological adaptability, genetic diversity, and multifaceted clinical relevance
- 25 August 2026
- Published by MDPI AG in Microorganisms
- Vol. 14 (9) , 1886
Open AccessLegionella pneumophila: A Microorganism with a Thousand Faces—From Environmental Complexity to Clinical and Technological Challenges
Legionella pneumophila epitomizes the concept of a microorganism with “a thousand faces”, reflecting its extraordinary ecological adaptability, genetic diversity, and multifaceted clinical relevance
- Open Access
Comorbidity Burden and Radiological Features Associated with Legionella pneumophila Pneumonia: A Retrospective Case–Control Study
Background: Legionella pneumophila is a leading cause of community- and hospital-acquired pneumonia (HAP/CAP), although the clinical and radiological features associated with infection remain incompletely defined. This study aimed to identify clinical, comorbidity-related, and chest computed tomography (CT) features associated with L. pneumophila pneumonia in hospitalized adults with community-acquired pneumonia (CAP). Methods: A retrospective case–control study was conducted at a tertiary-care university hospital in Italy between January 2019 and August 2025. Eighty patients positive for L. pneumophila were compared with 79 controls negative for L. pneumophila. Demographic, clinical, microbiological, and radiological data were collected, and factors independently associated with infection were evaluated using multivariable logistic regression analysis. Results: Patients with L. pneumophila infection exhibited a greater comorbidity burden, particularly heart failure, and were more frequently smokers. Bilateral lung involvement and hilar/mediastinal lymphadenopathy were significantly more common among Legionella-positive patients, whereas overall pulmonary complications and bilateral pleural effusion were more frequently observed in controls. Multivariable analysis identified comorbidity burden as an independent positive predictor of L. pneumophila infection, while intensive care unit admission, oxygen therapy, and pulmonary complication score were independently associated with a lower likelihood of infection. Conclusions: The integration of comorbidity assessment with readily available chest CT findings may help raise clinical suspicion of L. pneumophila pneumonia and support consideration of appropriate diagnostic testing.
Open AccessComorbidity Burden and Radiological Features Associated with Legionella pneumophila Pneumonia: A Retrospective Case–Control Study
Background: Legionella pneumophila is a leading cause of community- and hospital-acquired pneumonia (HAP/CAP), although the clinical and radiological features associated with infection remain incompletely defined. This study aimed to identify clinical, comorbidity-related, and chest computed tomography (CT) features associated with L. pneumophila pneumonia in hospitalized adults with community-acquired pneumonia (CAP). Methods: A retrospective case–control study was conducted at a tertiary-care university hospital in Italy between January 2019 and August 2025. Eighty patients positive for L. pneumophila were compared with 79 controls negative for L. pneumophila. Demographic, clinical, microbiological, and radiological data were collected, and factors independently associated with infection were evaluated using multivariable logistic regression analysis. Results: Patients with L. pneumophila infection exhibited a greater comorbidity burden, particularly heart failure, and were more frequently smokers. Bilateral lung involvement and hilar/mediastinal lymphadenopathy were significantly more common among Legionella-positive patients, whereas overall pulmonary complications and bilateral pleural effusion were more frequently observed in controls. Multivariable analysis identified comorbidity burden as an independent positive predictor of L. pneumophila infection, while intensive care unit admission, oxygen therapy, and pulmonary complication score were independently associated with a lower likelihood of infection. Conclusions: The integration of comorbidity assessment with readily available chest CT findings may help raise clinical suspicion of L. pneumophila pneumonia and support consideration of appropriate diagnostic testing.
- Open Access
- 22 July 2026
- Published by MDPI AG in Antibiotics
- Vol. 15 (7) , 711
Ranalexin-1G: A Promising Antimicrobial Peptide Targeting Virulence and Host–Pathogen Interactions in Pseudomonas aeruginosa In Vitro Models
Background: Lung infections represent a major cause of morbidity and mortality in patients with cystic fibrosis (CF) and are predominantly associated with chronic infection by Pseudomonas aeruginosa. The clinical management of CF lung disease is increasingly compromised by the emergence of multidrug-resistant strains, biofilm formation, and the expression of multiple virulence determinants. Antimicrobial peptides (AMPs), evolutionarily conserved effectors of innate immunity, have emerged as promising therapeutic candidates due to their ability to exert both bactericidal and anti-virulence activities. In this study, we investigated the antimicrobial and mechanistic effects of Ranalexin-1G, an AMP derived from the skin secretion of Rana grylio, against P. aeruginosa, for which its antibacterial activity has not previously been reported in the literature. Methods: Antibacterial activity was determined against the reference strain and three clinical isolates of P. aeruginosa by broth microdilution assays, time-kill kinetics and anti-biofilm assays, while peptide-mediated modulation of virulence was evaluated through transcriptional analysis of key virulence-associated genes by RT-PCR. The impact of Ranalexin-1G on host–pathogen interactions was further assessed using bacterial invasion assays in human bronchial epithelial cells (BEAS-2B). Results: Ranalexin-1G exerted a rapid bactericidal effect within 6 h at non-cytotoxic concentrations and displayed modest anti-biofilm effects, with greater efficacy in inhibiting biofilm formation. Mechanistically, peptide treatment resulted in a reduction in the expression of selected genes involved in biofilm formation and virulence, including those associated with alginate biosynthesis and type III secretion system-mediated cytotoxicity. Consistently, Ranalexin-1G markedly impaired bacterial invasion of epithelial cells, indicating interference with early host–pathogen interaction processes. Notably, the peptide displayed robust antimicrobial activity against multidrug-resistant P. aeruginosa clinical isolates from CF patients. Conclusions: Collectively, these findings suggest that Ranalexin-1G acts through a dual mechanism involving direct bactericidal activity and modulation of selected virulence pathways, supporting further investigation of its potential as an anti-virulence and host-directed approach for the treatment of chronic P. aeruginosa infections in cystic fibrosis.
- 22 July 2026
- Published by MDPI AG in Antibiotics
- Vol. 15 (7) , 711
Open AccessRanalexin-1G: A Promising Antimicrobial Peptide Targeting Virulence and Host–Pathogen Interactions in Pseudomonas aeruginosa In Vitro Models
Background: Lung infections represent a major cause of morbidity and mortality in patients with cystic fibrosis (CF) and are predominantly associated with chronic infection by Pseudomonas aeruginosa. The clinical management of CF lung disease is increasingly compromised by the emergence of multidrug-resistant strains, biofilm formation, and the expression of multiple virulence determinants. Antimicrobial peptides (AMPs), evolutionarily conserved effectors of innate immunity, have emerged as promising therapeutic candidates due to their ability to exert both bactericidal and anti-virulence activities. In this study, we investigated the antimicrobial and mechanistic effects of Ranalexin-1G, an AMP derived from the skin secretion of Rana grylio, against P. aeruginosa, for which its antibacterial activity has not previously been reported in the literature. Methods: Antibacterial activity was determined against the reference strain and three clinical isolates of P. aeruginosa by broth microdilution assays, time-kill kinetics and anti-biofilm assays, while peptide-mediated modulation of virulence was evaluated through transcriptional analysis of key virulence-associated genes by RT-PCR. The impact of Ranalexin-1G on host–pathogen interactions was further assessed using bacterial invasion assays in human bronchial epithelial cells (BEAS-2B). Results: Ranalexin-1G exerted a rapid bactericidal effect within 6 h at non-cytotoxic concentrations and displayed modest anti-biofilm effects, with greater efficacy in inhibiting biofilm formation. Mechanistically, peptide treatment resulted in a reduction in the expression of selected genes involved in biofilm formation and virulence, including those associated with alginate biosynthesis and type III secretion system-mediated cytotoxicity. Consistently, Ranalexin-1G markedly impaired bacterial invasion of epithelial cells, indicating interference with early host–pathogen interaction processes. Notably, the peptide displayed robust antimicrobial activity against multidrug-resistant P. aeruginosa clinical isolates from CF patients. Conclusions: Collectively, these findings suggest that Ranalexin-1G acts through a dual mechanism involving direct bactericidal activity and modulation of selected virulence pathways, supporting further investigation of its potential as an anti-virulence and host-directed approach for the treatment of chronic P. aeruginosa infections in cystic fibrosis.
- Open Access
Biliary Tract and Pancreatic Cancer (BTPC) in Adult Patients: The Role of the Biliary Microbiota in Cancer and Therapeutic Strategies—A Scoping Review
Background: The biliary and pancreatic tract is increasingly recognized as a microbial ecosystem rather than a sterile environment. Dysbiosis contributes to inflammation, bile acid alterations, and carcinogenesis, with distinct microbiota profiles linked to progression from benign to malignant conditions. Clinical factors, including gut–liver axis disruption and biliary stenting, may further exacerbate microbial imbalance. Objective: The objective of this study is to synthesize current evidence and identify knowledge gaps on the role of biliary microbiota in pancreaticobiliary carcinogenesis and its implications for diagnosis, prognosis, and therapy. Methods: This scoping review was conducted following PRISMA-ScR guidelines. A systematic search of PubMed, Web of Science, and Scopus was performed for studies published between January 2015 and December 2025, guided by the PICo framework. Results: Included studies primarily characterized changes in microbiota composition to identify microbial biomarkers associated with pancreaticobiliary diseases. Predictive bioinformatics analyses suggest that dysbiosis may promote carcinogenesis through metabolic and inflammatory pathways. Machine learning approaches identified microbiota-based signatures with potential diagnostic value for precancerous lesions, although discrimination remains limited. Biliary dysbiosis was also associated with outcomes related to biliary stenting, chemoprophylaxis, postoperative complications, and responses to chemotherapy or surgery. Conclusions: Integration of microbiota profiling with predictive bioinformatics and machine learning may improve understanding of pancreaticobiliary carcinogenesis. Identifying microbial and functional biomarkers could enable personalized diagnostic and therapeutic strategies, ultimately improving patient outcomes.
Open AccessBiliary Tract and Pancreatic Cancer (BTPC) in Adult Patients: The Role of the Biliary Microbiota in Cancer and Therapeutic Strategies—A Scoping Review
Background: The biliary and pancreatic tract is increasingly recognized as a microbial ecosystem rather than a sterile environment. Dysbiosis contributes to inflammation, bile acid alterations, and carcinogenesis, with distinct microbiota profiles linked to progression from benign to malignant conditions. Clinical factors, including gut–liver axis disruption and biliary stenting, may further exacerbate microbial imbalance. Objective: The objective of this study is to synthesize current evidence and identify knowledge gaps on the role of biliary microbiota in pancreaticobiliary carcinogenesis and its implications for diagnosis, prognosis, and therapy. Methods: This scoping review was conducted following PRISMA-ScR guidelines. A systematic search of PubMed, Web of Science, and Scopus was performed for studies published between January 2015 and December 2025, guided by the PICo framework. Results: Included studies primarily characterized changes in microbiota composition to identify microbial biomarkers associated with pancreaticobiliary diseases. Predictive bioinformatics analyses suggest that dysbiosis may promote carcinogenesis through metabolic and inflammatory pathways. Machine learning approaches identified microbiota-based signatures with potential diagnostic value for precancerous lesions, although discrimination remains limited. Biliary dysbiosis was also associated with outcomes related to biliary stenting, chemoprophylaxis, postoperative complications, and responses to chemotherapy or surgery. Conclusions: Integration of microbiota profiling with predictive bioinformatics and machine learning may improve understanding of pancreaticobiliary carcinogenesis. Identifying microbial and functional biomarkers could enable personalized diagnostic and therapeutic strategies, ultimately improving patient outcomes.
- Open Access
- 27 January 2026
- Published by Springer Nature in Journal of Anesthesia, Analgesia and Critical Care
- Vol. 6 (1)
The SIS NET ICU study: characteristics of patients with severe community acquired pneumonia admitted to Italian ICUs—a multicenter prospective observational study
The SIS-NET ICU study aimed to describe the epidemiology of severe community-acquired pneumonia (CAP) among patients admitted to Italian intensive care uni
- 27 January 2026
- Published by Springer Nature in Journal of Anesthesia, Analgesia and Critical Care
- Vol. 6 (1)
Open AccessThe SIS NET ICU study: characteristics of patients with severe community acquired pneumonia admitted to Italian ICUs—a multicenter prospective observational study
The SIS-NET ICU study aimed to describe the epidemiology of severe community-acquired pneumonia (CAP) among patients admitted to Italian intensive care uni
- Open Access
Community-Acquired Legionella pneumophila Pneumonia: A Case-Control Study in Adult Inpatients from 2019 to 2024
Background: Legionella pneumophila is frequently acquired in the community and generally linked to contaminated domestic hot water systems, hotels, or other environmental sources or of unknown origin. L. pneumophila is a leading cause of pneumonia, especially in high-risk patients such as those over 50 who are immunocompromised or people with pre-existing illnesses. This study examines the factors linked to L. pneumophila acquired in the community in adult patients with hospitalization due to pneumonitis. Methods: This case-control study included 140 hospitalized adult patients admitted to the University Hospital Paolo Giaccone of Palermo between January 2019 and December 2024. Demographic, laboratory, clinical, and microbiological data were collected electronically. Urinary antigen testing and the BioFire FilmArray Pneumonia Panel were used to detect L. pneumophila and were performed within 48 h upon admission. Results: Of 140 pneumonia patients, 70 were positive (SG) and 70 were negative (CG) for L. pneumophila. Comorbidities were significantly associated with the presence of L. pneumophila (p = 0.0046). The most frequent comorbidity was only heart failure (p < 0.0015) and, similarly, for smoke (p = 0.0487). There was no difference in mortality between the two groups (SG). Levofloxacin was the most frequent therapy used in SG (p < 0.0001). Additionally, SG showed significantly lower blood sodium, phosphate, and platelet levels (all p < 0.0001) compared to the CG. In contrast, blood parameters such as LDH, CRP, AST, and ALT were significantly higher (all p < 0.0001). Conclusions: Our research highlights the critical need for early detection of L. pneumophila infections, especially in patients with high CRP levels, moderate hypophosphatemia, or heart failure. In these patients with L. pneumophila, early treatment with macrolide and fluoroquinolone is mandatory to reduce mortality.
Open AccessCommunity-Acquired Legionella pneumophila Pneumonia: A Case-Control Study in Adult Inpatients from 2019 to 2024
Background: Legionella pneumophila is frequently acquired in the community and generally linked to contaminated domestic hot water systems, hotels, or other environmental sources or of unknown origin. L. pneumophila is a leading cause of pneumonia, especially in high-risk patients such as those over 50 who are immunocompromised or people with pre-existing illnesses. This study examines the factors linked to L. pneumophila acquired in the community in adult patients with hospitalization due to pneumonitis. Methods: This case-control study included 140 hospitalized adult patients admitted to the University Hospital Paolo Giaccone of Palermo between January 2019 and December 2024. Demographic, laboratory, clinical, and microbiological data were collected electronically. Urinary antigen testing and the BioFire FilmArray Pneumonia Panel were used to detect L. pneumophila and were performed within 48 h upon admission. Results: Of 140 pneumonia patients, 70 were positive (SG) and 70 were negative (CG) for L. pneumophila. Comorbidities were significantly associated with the presence of L. pneumophila (p = 0.0046). The most frequent comorbidity was only heart failure (p < 0.0015) and, similarly, for smoke (p = 0.0487). There was no difference in mortality between the two groups (SG). Levofloxacin was the most frequent therapy used in SG (p < 0.0001). Additionally, SG showed significantly lower blood sodium, phosphate, and platelet levels (all p < 0.0001) compared to the CG. In contrast, blood parameters such as LDH, CRP, AST, and ALT were significantly higher (all p < 0.0001). Conclusions: Our research highlights the critical need for early detection of L. pneumophila infections, especially in patients with high CRP levels, moderate hypophosphatemia, or heart failure. In these patients with L. pneumophila, early treatment with macrolide and fluoroquinolone is mandatory to reduce mortality.
- Open Access
- 3 November 2025
- Published by MDPI AG in Infectious Disease Reports
- Vol. 17 (6) , 137
Difficult-to-Treat Skin and Soft Tissue Infections Caused by Panton-Valentine Leukocidin-Producing Community-Associated Methicillin-Resistant Staphylococcus aureus: A Case Series
Background: Community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) has emerged as a genetically distinct lineage from healthcare-associated MRSA (HA-MRSA), often producing Panton-Valentine leukocidin (PVL) and causing severe skin and soft tissue infections (SSTIs) in otherwise healthy individuals. Methods: We describe five cases of PVL-positive CA-MRSA SSTIs admitted to the Infectious Diseases Unit of the University Hospital “Paolo Giaccone,” Palermo, Italy, between 2024 and 2025. Case inclusion followed the CDC criteria for CA-MRSA. Microbiological identification was performed using MALDI-TOF mass spectrometry, and antimicrobial susceptibility testing followed EUCAST standards. PVL gene presence was confirmed by polymerase chain reaction. Results: Clinical management included surgical drainage, systemic antibiotic therapy, and decolonization of both patients and close contacts. Long-acting lipoglycopeptides (oritavancin or dalbavancin) were evaluated as therapeutic options to achieve clinical resolution. Conclusions: PVL-positive CA-MRSA infections are characterized by recurrence, intrafamilial clustering, and frequent therapeutic failure with standard oral agents. Effective management requires an integrated approach combining prompt surgical drainage; systemic therapy, preferably including long-acting lipoglycopeptides; and comprehensive decolonization of all close contacts.
- 3 November 2025
- Published by MDPI AG in Infectious Disease Reports
- Vol. 17 (6) , 137
Open AccessDifficult-to-Treat Skin and Soft Tissue Infections Caused by Panton-Valentine Leukocidin-Producing Community-Associated Methicillin-Resistant Staphylococcus aureus: A Case Series
Background: Community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) has emerged as a genetically distinct lineage from healthcare-associated MRSA (HA-MRSA), often producing Panton-Valentine leukocidin (PVL) and causing severe skin and soft tissue infections (SSTIs) in otherwise healthy individuals. Methods: We describe five cases of PVL-positive CA-MRSA SSTIs admitted to the Infectious Diseases Unit of the University Hospital “Paolo Giaccone,” Palermo, Italy, between 2024 and 2025. Case inclusion followed the CDC criteria for CA-MRSA. Microbiological identification was performed using MALDI-TOF mass spectrometry, and antimicrobial susceptibility testing followed EUCAST standards. PVL gene presence was confirmed by polymerase chain reaction. Results: Clinical management included surgical drainage, systemic antibiotic therapy, and decolonization of both patients and close contacts. Long-acting lipoglycopeptides (oritavancin or dalbavancin) were evaluated as therapeutic options to achieve clinical resolution. Conclusions: PVL-positive CA-MRSA infections are characterized by recurrence, intrafamilial clustering, and frequent therapeutic failure with standard oral agents. Effective management requires an integrated approach combining prompt surgical drainage; systemic therapy, preferably including long-acting lipoglycopeptides; and comprehensive decolonization of all close contacts.
- Open Access
Human Papillomavirus: An Old New History
Human papillomavirus (HPV) represents the most common sexually transmitted infection worldwide and a major public health challenge. Nearly all sexually active individuals will acquire HPV during their lifetime, with the highest prevalence observed in adolescents and young adults shortly after sexual debut. More than 200 genotypes have been described, ranging from low-risk types, mainly responsible for benign lesions, to high-risk types, which are associated with cervical, anogenital, and head and neck cancers. While most infections are transient and spontaneously cleared by the immune system, persistent high-risk HPV can lead to precancerous lesions and malignant transformation, often in synergy with other sexually transmitted pathogens or in the context of microbiome imbalance. The introduction of vaccines and advanced screening technologies has substantially modified prevention strategies. Vaccination coverage remains heterogeneous, with persistent gaps particularly among males due to cultural, social, and educational barriers. Schools are increasingly recognized as strategic environments to promote awareness, sex education, and gender-neutral vaccination. Innovative approaches such as microbiome modulation, therapeutic vaccines, and liquid biopsy biomarkers are emerging as promising perspectives. This review aims to provide an updated overview of HPV epidemiology, clinical impact, prevention strategies, and future frontiers, with special attention to adolescents as a priority target group.
Open AccessHuman Papillomavirus: An Old New History
Human papillomavirus (HPV) represents the most common sexually transmitted infection worldwide and a major public health challenge. Nearly all sexually active individuals will acquire HPV during their lifetime, with the highest prevalence observed in adolescents and young adults shortly after sexual debut. More than 200 genotypes have been described, ranging from low-risk types, mainly responsible for benign lesions, to high-risk types, which are associated with cervical, anogenital, and head and neck cancers. While most infections are transient and spontaneously cleared by the immune system, persistent high-risk HPV can lead to precancerous lesions and malignant transformation, often in synergy with other sexually transmitted pathogens or in the context of microbiome imbalance. The introduction of vaccines and advanced screening technologies has substantially modified prevention strategies. Vaccination coverage remains heterogeneous, with persistent gaps particularly among males due to cultural, social, and educational barriers. Schools are increasingly recognized as strategic environments to promote awareness, sex education, and gender-neutral vaccination. Innovative approaches such as microbiome modulation, therapeutic vaccines, and liquid biopsy biomarkers are emerging as promising perspectives. This review aims to provide an updated overview of HPV epidemiology, clinical impact, prevention strategies, and future frontiers, with special attention to adolescents as a priority target group.
- Open Access
- 10 October 2025
- Published by MDPI AG in Antibiotics
- Vol. 14 (10) , 1007
Imipenem/Relebactam Plus Aztreonam: First Reported Use in MDR Klebsiella pneumoniae Sternal Infection Complicated by Bacteremia
Background: Carbapenem-resistant Klebsiella pneumoniae (CRKP) poses a significant therapeutic challenge, particularly when multiple resistance mechanisms, such as metallo-β-lactamases (MBLs) and Klebsiella pneumoniae carbapenemase (KPC), coexist. Case description: We describe a case of a 51-year-old male with a post-sternotomy surgical site infection and concurrent bacteremia caused by a CRKP. Sternal swab and mediastinal liquid culture results highlighted CRKP harboring blaNDM and blaKPC genes, while the blood isolate showed blaCTX and blaKPC, indicating phenotypic resistance to ceftazidime-avibactam. All the strains exhibited phenotypic susceptibility to meropenem-vaborbactam (MEV), despite having a high minimum inhibitory concentration. Following clinical failure of MEV-based therapy, combination treatment with aztreonam (ATM) and imipenem/cilastatin/relebactam (IMI/REL), plus gentamicin, was initiated. Therapy was well tolerated and resulted in microbiological eradication and full clinical recovery. The patient completed 49 days of ATM and IMI/REL without relapse over a 3-month follow-up period. This is, to the best of our knowledge, the first reported case of IMI/REL being used in combination with ATM.
- 10 October 2025
- Published by MDPI AG in Antibiotics
- Vol. 14 (10) , 1007
Open AccessImipenem/Relebactam Plus Aztreonam: First Reported Use in MDR Klebsiella pneumoniae Sternal Infection Complicated by Bacteremia
Background: Carbapenem-resistant Klebsiella pneumoniae (CRKP) poses a significant therapeutic challenge, particularly when multiple resistance mechanisms, such as metallo-β-lactamases (MBLs) and Klebsiella pneumoniae carbapenemase (KPC), coexist. Case description: We describe a case of a 51-year-old male with a post-sternotomy surgical site infection and concurrent bacteremia caused by a CRKP. Sternal swab and mediastinal liquid culture results highlighted CRKP harboring blaNDM and blaKPC genes, while the blood isolate showed blaCTX and blaKPC, indicating phenotypic resistance to ceftazidime-avibactam. All the strains exhibited phenotypic susceptibility to meropenem-vaborbactam (MEV), despite having a high minimum inhibitory concentration. Following clinical failure of MEV-based therapy, combination treatment with aztreonam (ATM) and imipenem/cilastatin/relebactam (IMI/REL), plus gentamicin, was initiated. Therapy was well tolerated and resulted in microbiological eradication and full clinical recovery. The patient completed 49 days of ATM and IMI/REL without relapse over a 3-month follow-up period. This is, to the best of our knowledge, the first reported case of IMI/REL being used in combination with ATM.
- Open Access
- 1 October 2025
- Published by MDPI AG in Parasitologia
- Vol. 5 (4) , 51
Abdominal Subcutaneous Dirofilariasis Due to Dirofilaria repens in a 34-Year-Old Sicilian Woman: Diagnostic Challenges and Molecular Confirmation
Human subcutaneous dirofilariasis caused by Dirofilaria repens is an emerging zoonotic parasitic infection increasingly observed in southern Europe. We report a case of a woman from western Sicily, who likely acquired the infection locally through a mosquito bite. The high prevalence of D. repens in the local canine population (up to 20.4%) suggests a role of dogs as a probable reservoir for transmission to humans in the local population. With ultrasound analysis being inconclusive, only after surgical removal was the presence of an adult worm evident, and only after molecular analysis through DNA sequencing of the cytochrome oxidase subunit I gene (COI) could a definitive D. repens infection diagnosis be obtained. This case highlights the need for enhanced vector control, animal health surveillance and public awareness to limit the transmission to humans of D. repens. A correct parasitological diagnosis would be imperative for the recognition of human cases.
- 1 October 2025
- Published by MDPI AG in Parasitologia
- Vol. 5 (4) , 51
Open AccessAbdominal Subcutaneous Dirofilariasis Due to Dirofilaria repens in a 34-Year-Old Sicilian Woman: Diagnostic Challenges and Molecular Confirmation
Human subcutaneous dirofilariasis caused by Dirofilaria repens is an emerging zoonotic parasitic infection increasingly observed in southern Europe. We report a case of a woman from western Sicily, who likely acquired the infection locally through a mosquito bite. The high prevalence of D. repens in the local canine population (up to 20.4%) suggests a role of dogs as a probable reservoir for transmission to humans in the local population. With ultrasound analysis being inconclusive, only after surgical removal was the presence of an adult worm evident, and only after molecular analysis through DNA sequencing of the cytochrome oxidase subunit I gene (COI) could a definitive D. repens infection diagnosis be obtained. This case highlights the need for enhanced vector control, animal health surveillance and public awareness to limit the transmission to humans of D. repens. A correct parasitological diagnosis would be imperative for the recognition of human cases.